Among the critical quality attributes (CQAs), the polyadenosine (Poly(A)) tail at the 3' end plays a non-negotiable role in determining the molecule's fate. This homopolymeric stretch of adenosine residues is not merely a terminal sequence; it acts as a primary regulator of mRNA stability, protection against exonuclease-mediated degradation, and recruitment of the translation machinery. At CD BioGlyco, we recognize that even minor deviations in Poly(A) length lead to significant fluctuations in protein expression levels and therapeutic half-life. Our mRNA Poly(A) tail length analysis service provides a high-resolution, quantitative map of tail distribution. By leveraging advanced analytical platforms, we enable researchers to optimize mRNA vaccine candidates and gene therapy vectors, ensuring that every transcript is engineered for maximum potency and stability.
As a pivotal component of our therapeutic nucleic acid development platform, CD BioGlyco offers an end-to-one structural characterization suite specifically designed for mRNA-based vaccine development. Our mRNA structural characterization services focus on the rigorous quantification of the Poly(A) tail, recognizing it as a vital determinant of vaccine efficacy. Our scope extends beyond simple length measurement.
Whether you are working with in vitro transcribed (IVT) mRNA or samples extracted from biological matrices, our service is tailored to validate the success of your tailing strategies.
Upon receipt, every mRNA sample undergoes a rigorous intake QC. We assess purity and integrity using the bioanalyzer or fragment analyzer to ensure the RNA integrity number (RIN) meets the threshold for high-resolution structural analysis.
Since intact mRNA is often too large for direct high-resolution MS analysis, we perform controlled enzymatic digestion. Using sequence-specific ribonucleases, we precisely cleave the mRNA to liberate the Poly(A) tail while keeping the coding region and untranslated regions (UTRs) separate.
To eliminate background noise from the coding sequence fragments, we utilize oligo(dT) magnetic bead capture or specialized chromatographic resins. This step ensures that the subsequent analytical signals are derived exclusively from the 3' tail population.
The enriched fragments are processed via IP-RP-HPLC or CE. Our optimized solvent systems and temperature controls prevent the formation of secondary structures, ensuring that the separation is purely dependent on the length of the adenosine chain.
The eluent is introduced into a high-resolution MS. Deconvolution algorithms are then applied to the raw mass spectra to determine the exact number of nucleotides in each sub-population of the tail.
We generate distribution histograms, calculate the polydispersity index, and provide a detailed report that correlates the structural data with the expected biological performance of your mRNA candidate.
DoI: 10.1038/s41597-024-04226-8
Journal: Scientific Data
IF: 6.9
Published: 2025
Results: This study presents a comprehensive dataset on mRNA poly(A) tail composition and dynamics in mouse testes and ovaries, using Oxford Nanopore Direct RNA Sequencing (DRS) and Illumina RNA-seq. It focuses on wild-type mice and those with TENT5 polymerase knockouts (linked to infertility). The DRS method, paired with the Ninetails algorithm, enables accurate analysis of poly(A) tail length and non-adenosine residues (e.g., uridines, prevalent in testicular mRNAs near tail ends). Illumina data supplements differential gene expression insights. Key findings include uridine-enriched poly(A) tails in spermatogenesis-critical transcripts and TENT5c knockout impacts on germ cell gene expression.
Fig.1 Schematic representation of the non-adenosine analysis workflow. (Czarnocka-Cieciura, et al., 2025)
Vaccine Efficacy Optimization
By determining the optimal Poly(A) length that maximizes antigen expression, developers enhance the immunogenicity of mRNA vaccines while potentially reducing the required dosage.
mRNA Stability and Shelf-Life Studies
Our analysis identifies the rate of deadenylation under various storage conditions, providing critical data for the development of stable formulations and the establishment of expiration dating for biotherapeutics.
Gene Therapy Development
We ensure that the mRNA vectors possess the structural features necessary for sustained cytoplasmic persistence and efficient recruitment of the eukaryotic initiation factor 4F (eIF4F) complex.
Manufacturing Process Validation
We assist in validating the consistency of enzymatic polyadenylation versus template-encoded tailing, ensuring that the manufacturing process yields a uniform product that meets the specifications for identity and purity.
Single-Nucleotide Resolution
Our LC-MS/MS platforms provide unmatched precision, allowing us to distinguish between tails differing by only one adenosine residue, ensuring the most accurate heterogeneity profiling available in the industry.
Flexible Analytical Platforms
We offer a choice between MS and NGS-based methods, allowing us to customize the approach based on your specific sample type, required throughput, and budget without compromising data quality.
Minimal Sample Requirement
CD BioGlyco generates comprehensive Poly(A) profiles from microgram or even nanogram quantities of mRNA, preserving your valuable therapeutic material for other critical assays.
Expert Data Interpretation
Our PhD-level scientists do not just provide raw data; we offer deep insights into how the observed Poly(A) distribution may impact your mRNA's stability and translational efficiency based on years of experience.
"We were able to identify a sub-population of truncated tails that was negatively impacting our vaccine's expression levels. Their insights allowed us to refine our IVT process significantly."
– A.R., Senior Scientist
"Their technical team understands the nuances of mRNA structural characterization, and the LC-MS data was instrumental. Highly recommended for any nucleic acid therapeutic developer."
– E.T., Director of Analytical R&D
"We needed a rapid turnaround for a batch comparison study. The clarity of the reports and the depth of the statistical analysis made it easy for our team to make manufacturing adjustments."
– B.T., Principal Investigator
CD BioGlyco is committed to providing the most advanced analytical solutions for the burgeoning field of mRNA therapeutics. Our mRNA Poly(A) tail length analysis service stands at the intersection of cutting-edge technology and deep biological expertise, ensuring your candidates are built on a foundation of structural perfection. Please feel free to contact us for detailed information on our services or to request a formal quotation.
Reference
